Lothar Mϋller

12PUBLICATIONS

77CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (12)

Sort by Publication Date:

|Jun 20, 2026

Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

|Jan 05, 2026

Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer.

Julius Keyl, René Hosch, Fabian Hörst

|Nov 18, 2025

Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer.

Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing

|Jul 30, 2025

Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial.

Alexej Ballhausen, Susanna Swoboda, David Horst

|Mar 18, 2025

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia.

Valentin Goede, Kirsten Fischer, Sandra Robrecht

|Nov 27, 2024

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Petra Langerbeins, Sandra Robrecht, Pascal Nieper

Pageof 2

Frequent Collaborators

Dominik Paul Modest

Arndt Stahler

Sebastian Stintzing

Ullrich Graeven

Annika Kurreck

Volker Heinemann

Petra Langerbeins

Annabel Helga Sophie Alig

3 joint publications

Anke Reinacher-Schick

3 joint publications

Stefan Fruehauf

Frequent Collaborators

Dominik Paul Modest

Arndt Stahler

Sebastian Stintzing

Ullrich Graeven